BioMarin (BMRN) Tops Q2 EPS by 18c, Sells riority Review Voucher for $67.5 Million

BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q2 EPS of ($0.23), $0.18 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $191.8 million versus the consensus estimate of $159.7 million.

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has sold the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in February of this year. The Company received the voucher under an FDA program intended to encourage the development of treatments for rare pediatric diseases. BioMarin was awarded the voucher when it received approval of VIMIZIM®, a new biological product for patients with Mucopolysaccharidosis type IVA, also known as Morquio A syndrome. BioMarin received $67.5 million from Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals, Inc., in exchange for the voucher.

For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks
• UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy